Equities

Invent Medic Sweden AB

Invent Medic Sweden AB

Actions
  • Price (SEK)0.332
  • Today's Change0.02 / 6.41%
  • Shares traded603.00
  • 1 Year change-62.04%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1.553.0516
Total Receivables, Net0.920.970.97
Total Inventory0.620.790.66
Prepaid expenses0.281.100.47
Other current assets, total------
Total current assets3.365.9218
Property, plant & equipment, net0.210.240.36
Goodwill, net------
Intangibles, net2.573.213.64
Long term investments4.21----
Note receivable - long term------
Other long term assets------
Total assets109.3622
LIABILITIES
Accounts payable0.260.651.26
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.521.720.67
Other current liabilities, total0.140.120.20
Total current liabilities2.603.313.19
Total long term debt2.270.671.33
Total debt3.792.382.00
Deferred income tax------
Minority interest------
Other liabilities, total0.33----
Total liabilities5.203.984.52
SHAREHOLDERS EQUITY
Common stock4.022.582.58
Additional paid-in capital928585
Retained earnings (accumulated deficit)(91)(83)(71)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00.290.69
Total equity5.145.3817
Total liabilities & shareholders' equity109.3622
Total common shares outstanding422828
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.